Related Experiment Videos
Spanish Menopause Society position statement: Use of denosumab in postmenopausal women
Antonio Cano1, José Manuel Silvan2, Antonio Estévez3
1Hospital Universitario Dr Peset, University of Valencia, Valencia, Spain.
Abstract:
Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.
Insights
Denosumab effectively manages bone loss in osteoporosis and cancer-related conditions. This expert panel developed recommendations for its use, particularly for postmenopausal women undergoing cancer treatment.
Area of Science:
- Oncology
- Endocrinology
- Bone Metabolism
Background:
- Denosumab is a novel therapeutic agent.
- Emerging evidence suggests denosumab's utility in oncological applications.
- Its role in managing bone loss during cancer therapy is gaining attention.
Purpose of the Study:
- To provide expert recommendations for denosumab usage.
- To address the application of denosumab in postmenopausal women's health.
- To consolidate evidence regarding denosumab's efficacy in cancer-related bone conditions.
Main Methods:
- Expert panel convened by the Spanish Menopause Society.
- Review of current scientific literature and clinical evidence.
- Development of evidence-based usage guidelines.
Main Results:
- Denosumab demonstrates efficacy in controlling chemotherapy-induced bone loss.
- Evidence supports denosumab's role in managing hypogonadic states.
- Potential benefits in reducing cancer metastasis progression are noted.
Conclusions:
- Denosumab is a valuable option for osteoporosis management.
- Recommendations focus on its application in cancer patients, especially postmenopausal women.
- Further research may elucidate broader applications in oncology and bone health.